Pavlos Msaouel

Assistant Professor - Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center.

Seminars

Monday 18th May 2026
Introducing Myriad’s Ultra-Sensitive Tumor Informed MRD Assay
4:00 pm - 6:00 pm

Join us for a hosted learning and networking engager in partnership with Myriad Genetics 

Join this deep-dive session to understand how ultra-sensitive, tumor-informed MRD  testing is being applied across real clinical and development settings. Hear how  leading experts are translating MRD data into actionable decisions across patient  management, trial design, and therapeutic development. Walk away with a clear view of where MRD delivers value today and how to apply it across your own programs.

Register your interest* to attend

*Attendance subject to availability and partner approval. For T&Cs please visit website.

Tuesday 19th May 2026
Circulating KIM-1 & ctDNA as Prognostic Markers in Oligometastatic Clear Cell Renal Cell Carcinoma (ccRCC): The K-COMPASS Model
3:00 pm
  • Biomarker assay development, validation & clinical testing solutions tailored for drug programmes 
  • Flexible platforms, chemistries & technologies for multiple diseases indications 
  • Support for global regulatory strategies including EU (IVDR) and FDA
  • Pharma Case Study: Learn how Almac has supported Global clinical studies

Pavlos Msaouel